These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39349713)

  • 1. Comment on - Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
    Chellapandian H; Jeyachandran S
    Neurosurg Rev; 2024 Oct; 47(1):708. PubMed ID: 39349713
    [No Abstract]   [Full Text] [Related]  

  • 2. Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
    Habibi MA; Shad N; Mirjnani MS; Fasihi S; Sadeghi S; Karami S; Ahmadvand MH; Delbari P; Zare AH; Zare AH; Alavi SAN
    Neurosurg Rev; 2024 Aug; 47(1):445. PubMed ID: 39162874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme.
    Yang F; Wang L; Zhao W; Wang S; Li J; Sun A; Wang M; Wang Z; Chen Z; Heng X
    Neurol India; 2024 Jul; 72(4):700-707. PubMed ID: 39216020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma.
    Wilson L; Atallah A; Romero JM
    J Neurooncol; 2024 Jun; 168(2):375-376. PubMed ID: 38619776
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
    J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
    Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
    J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
    Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y;
    BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
    Gholamin S; Youssef OA; Rafat M; Esparza R; Kahn S; Shahin M; Giaccia AJ; Graves EE; Weissman I; Mitra S; Cheshier SH
    Innate Immun; 2020 Feb; 26(2):130-137. PubMed ID: 31547758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
    Wang Y; Feng Y
    Clin Neurol Neurosurg; 2020 Sep; 196():105890. PubMed ID: 32623215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
    Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
    J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter to the Editor Regarding "Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis".
    Zhang L
    World Neurosurg; 2024 Sep; 189():499. PubMed ID: 39252341
    [No Abstract]   [Full Text] [Related]  

  • 12. A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
    O'Toole L; Khanduri S; Gerrard GE
    Clin Oncol (R Coll Radiol); 2007 May; 19(4):269. PubMed ID: 17433972
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
    Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
    J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapeutic options for glioblastoma and future perspectives.
    Aquilanti E; Wen PY
    Expert Opin Pharmacother; 2022 Oct; 23(14):1629-1640. PubMed ID: 36100970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
    Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
    J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to T.J. Kruser et al.
    Chinot OL; Taphoorn MJ; Bais C; Bourgon R; Phillips HS; Abrey LE; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Cloughesy T
    J Clin Oncol; 2016 Apr; 34(11):1282-3. PubMed ID: 26884575
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
    Chua J; Nafziger E; Leung D
    Curr Oncol Rep; 2019 Mar; 21(4):30. PubMed ID: 30835007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
    Kruser TJ; Mehta MP; Kozak KR
    J Clin Oncol; 2016 Apr; 34(11):1281-2. PubMed ID: 26884565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.